Sage Therapeutics (NASDAQ:SAGE) is reportedly suing Biogen (NASDAQ:BIIB) over enforcement of a standstill agreement in the ...

Sage Therapeutics Inc. sued Biogen Inc. on Friday, a week after the biotech giant made an unsolicited offer to acquire the ...

Analysts say the deal, which would give Biogen full control over the drug Zurzuvae, could be a smart financial move. Yet it's ...

Sage Therapeutics' financials indicate a need for additional funding in 2025, risking dilution and further financial ...

Truist keeps a Hold rating on Sage Therapeutics (SAGE) after Zurzurvae’s commercial partner Biogen (BIIB) disclosed an unsolicited proposal to ...

Biogen is looking to augment growth by hunting for biotechs with drugs in mid- and late-stage clinical development.

Sage stock rose 35% to $7.51 in premarket trading Monday; it closed at $5.55 on Friday. Biogen shares dipped 0.5% to $48.01.

The $7.22-per-share deal for 89.8% of Sage is a 30% premium on the company's share price on Friday and is estimated by ...

Biogen’s proposed acquisition comes after two difficult years of regulatory and clinical challenges, during which shares of ...

Sage Therapeutics, Inc. (Nasdaq: SAGE) saw its stock price soar by an impressive 33.87%, reaching $7.43 during Monday’s premarket trading session. The surge came on the heels of the company’s ...

Today's sure has SAGE on track for its largest single-day percentage gain since January 2019. Though further removed from ...

Biogen proposes acquiring Sage Therapeutics for $7.22 per share, as analysts highlight the strategic value of Zurzuvae's ...